Profile data is unavailable for this security.
About the company
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-25.86m
- Incorporated2011
- Employees6.00
- LocationNeximmune Inc9119 Gaither RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (301) 825-9810
- Fax+1 (302) 636-5454
- Websitehttps://www.neximmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alzamend Neuro Inc | 0.00 | -12.40m | 2.88m | 4.00 | -- | -- | -- | -- | -1.87 | -1.87 | 0.00 | -0.572 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 2.90m | 24.00 | -- | -- | -- | 0.2037 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Petros Pharmaceuticals Inc | 4.69m | -20.46m | 2.91m | 21.00 | -- | 0.2918 | -- | 0.619 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
Aditxt Inc | 506.45k | -41.45m | 2.91m | 47.00 | -- | 0.2448 | -- | 5.75 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
Portage Biotech Inc | 0.00 | -144.90m | 2.99m | 7.00 | -- | 0.0933 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
Zyversa Therapeutics Inc | 0.00 | -105.53m | 3.06m | 7.00 | -- | 0.2727 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Avenue Therapeutics Inc | 0.00 | -7.18m | 3.15m | 3.00 | -- | 0.6961 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
GB Sciences Inc | 0.00 | -4.03m | 3.23m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
Neximmune Inc | 0.00 | -25.86m | 3.25m | 6.00 | -- | 1.18 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
Novelstem International Corp | 15.00k | -4.22m | 3.37m | 15.00 | -- | -- | -- | 224.72 | -0.09 | -0.09 | 0.0003 | -0.0478 | 0.0065 | -- | 10.00 | -- | -172.16 | -- | -1,011.77 | -- | -- | -- | -26,418.53 | -- | -- | -8.40 | 2.34 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
Aridis Pharmaceuticals Inc | 22.36m | -1.14m | 3.41m | 37.00 | -- | -- | -- | 0.1525 | -0.1845 | -0.1845 | 0.7074 | -0.2648 | 2.40 | -- | 58.45 | 604,297.30 | -12.24 | -120.16 | -- | -678.29 | -- | -- | -5.11 | -1,559.63 | -- | -- | -- | -- | 101.37 | 29.16 | 34.43 | -- | -34.84 | -- |
Ensysce Biosciences Inc | 1.75m | -11.55m | 3.49m | 7.00 | -- | 0.8993 | -- | 2.00 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 3.50m | 5.00 | -- | 1.26 | -- | 7.33 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
OpGen Inc | 3.42m | -32.67m | 3.59m | 100.00 | -- | -- | -- | 1.05 | -40.91 | -40.91 | 4.35 | -9.01 | 0.2469 | 5.22 | 11.07 | -- | -235.91 | -87.95 | -1,149.98 | -127.65 | -2.65 | 15.42 | -955.69 | -794.78 | 0.1383 | -8.17 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
Holder | Shares | % Held |
---|---|---|
Sabby Management LLCas of 31 Mar 2024 | 59.85k | 4.37% |
Slate Path Capital LPas of 31 Mar 2024 | 37.00k | 2.70% |
EPIQ Capital Group LLCas of 31 Mar 2024 | 15.62k | 1.14% |
PNC Bank, NA (Investment Management)as of 31 Mar 2024 | 12.64k | 0.92% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 12.01k | 0.88% |
Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 10.80k | 0.79% |
Comerica Bank (Investment Management Texas)as of 31 Mar 2024 | 3.26k | 0.24% |
Tower Research Capital LLCas of 31 Mar 2024 | 1.58k | 0.12% |
RBC Dominion Securities, Inc.as of 31 Mar 2024 | 173.00 | 0.01% |
BNP Paribas Financial Marketsas of 31 Mar 2024 | 41.00 | 0.00% |